New Investigative Therapy for Methylmalonic Acidemia and Propionic Acidemia is Making Regulatory Progress
source: pixabay.com

New Investigative Therapy for Methylmalonic Acidemia and Propionic Acidemia is Making Regulatory Progress

Fast Track Designation and Rare Pediatric Disease Designation have just been awarded from the FDA to HemoShear Therapeutics. This designation was given to their new investigative therapy for propionic acidemia…

Continue Reading New Investigative Therapy for Methylmalonic Acidemia and Propionic Acidemia is Making Regulatory Progress
Company Receives Clearance to Conduct Trial for Propionic and Methylmalonic Acidemia
source: pixabay.com

Company Receives Clearance to Conduct Trial for Propionic and Methylmalonic Acidemia

According to a press release from HemoShear Therapeutics, the company has recently received official clearance from the US Food and Drug Administration (FDA) in regards to its Investigational New Drug…

Continue Reading Company Receives Clearance to Conduct Trial for Propionic and Methylmalonic Acidemia
First Patient Enrolled in a New Methylmalonic Acidemia Trial
source: pixabay.com

First Patient Enrolled in a New Methylmalonic Acidemia Trial

Methylmalonic Acidemia Methylmalonic acidemia (MMA) is a rare disease affecting the metabolic system. 60% of all cases are due to a deficiency in MUT, a mitochondrial enzyme, which causes acids to…

Continue Reading First Patient Enrolled in a New Methylmalonic Acidemia Trial
Preclinical Data Looks Promising for Antibody Against Chikungunya
kalhh / Pixabay

Preclinical Data Looks Promising for Antibody Against Chikungunya

According to a story from Acrofan, the biotechnology company Moderna, Inc. recently released the results of a preclinical study which described the use of mRNA which encodes a monoclonal antibody…

Continue Reading Preclinical Data Looks Promising for Antibody Against Chikungunya
Close Menu